

Statement regarding the use of opioid analgesics in patients with chronic non-cancer pain

Preamble

- A. The Faculty of Pain Medicine (FPM) recognises the lack of definitive evidence supporting the long-term effectiveness of opioid analgesics in people experiencing chronic non-cancer pain (CNCP) and the substantial evidence for potential harm.
- B. The FPM recognises that opioids are widely and often inappropriately prescribed for CNCP despite the lack of clear evidence of efficacy.
- C. The FPM also recognises the changed regulatory environment introduced in Australia by the TGA¹ in 2020, specifically²:
- “[Modified-release opioid product] is indicated for the management of severe pain where
- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and
 - the pain is opioid-responsive, and
 - requires daily, continuous, long-term treatment.
- “[Modified-release opioid product] is not indicated for use in chronic non-cancer pain other than in exceptional circumstances.”
- D. The FPM interprets “exceptional circumstances” in this context to denote:
- Severe pain,
 - for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management,
 - and*
 - which has been shown to be opioid-responsive
- E. In New Zealand, Medsafe has not taken an overarching regulatory approach. The indications for each drug are listed in its data sheet.³ Some but not all products mention criteria such as opioid-responsiveness, failure of conservative methods of analgesia, and absence of psychological contraindication, drug-seeking behaviour or history of drug misuse. CNCP is not necessarily specified.
- F. This document describes the current position of the FPM regarding the prescription of opioids in CNCP, presented as a series of principles and a synopsis of the evidence and reasoning on which they are based.

¹ Therapeutic Goods Administration, Department of Health, Commonwealth of Australia

² Therapeutics Good Administration. Prescription opioids hub: Upcoming changes to reduce harm. <https://www.tga.gov.au/node/877210>: TGA, 2020. Accessed 11/3/2020.

³ [https://www.medsafe.govt.nz/Profs/Datasheet/\[product\]](https://www.medsafe.govt.nz/Profs/Datasheet/[product]) Accessed 31/3/2020.

PRINCIPLES

1. GENERAL PRINCIPLES INFORMING THE MANAGEMENT OF PATIENTS WITH CHRONIC NON-CANCER PAIN

- 1.1 Careful assessment of the social, psychological and biomedical contributors⁴ to the person's presentation should be undertaken to inform a management plan for people with CNCP.
- 1.2 The first line of therapy for CNCP involves engaging the person to develop pain self-management skills⁵.
- 1.3 Second line therapies in CNCP include drug treatment which, while not a core component of a management plan, may play a role in facilitating functional goals and maintaining social roles including employment.
- 1.4 Drug treatment for the patient with CNCP is only ever part of a multimodal plan towards self-management and should be prescribed on a time-limited basis.
- 1.5 Drug treatment with opioids in patients with CNCP may be considered in the exceptional circumstances described in Preamble point D above.

2. PRINCIPLES INFORMING THE PRESCRIPTION OF OPIOIDS TO PATIENTS WITH CHRONIC NON-CANCER PAIN

2.1 General

- 2.1.1 Opioid treatment in CNCP is always an ongoing individual trial of therapy. Prescription of opioids, in the context of Principle 1.5 above, is contingent upon:
 - demonstration of benefit;
 - active surveillance for harms; and
 - periodic attempts at dose minimisation.
- 2.1.2 It is the responsibility of each prescriber to be thoroughly acquainted with:
 - the clinical pharmacology of the opioid(s) to be prescribed;
 - the efficacy and harms of those opioids;
 - the interactions of opioids with their individual patient's health, other drugs and social context.
 - the recommendations for and local availability of take-home naloxone (THN) and THN patient-education; and
 - the regulatory requirements imposed by the jurisdiction in which they practise.

To maximise opioid safety, timely administration of naloxone could save a life. FPM ANZCA provides the following guidance on take home naloxone (THN):

1. Prescribers **consider THN** and patient-education with **ALL out-patient** opioid prescriptions, adjusted for individual risk
2. Prescribers **recommend THN** and patient-education with an **oMEDD > 40mg**, adjusted for individual risk

For more detail, see *Prescribing Opioids Safely* below.

⁴ Sociopsychobiomedical Assessment. Faculty of Pain Medicine, ANZCA, Curriculum 2015-.

⁵ Pain self-management skills development is a process where a person learns ways to manage their symptoms and achieve goals (Nicholas & Blyth. Pain Management, 2016;6(1):75-88).
<http://fpm.anzca.edu.au/training/2015-training-program.2015>.

- 2.1.3 The aim of an opioid analgesic trial is to discover the individual's responsiveness to this therapy in terms of improved quality of life. This requires clear articulation of the goals of the trial, including an agreement that if the goals are not met, then this treatment will be withdrawn.⁶
- Such goals extend beyond pain relief alone, to include improvement in activity and participation.⁷ Goals need to be negotiated according to the individual's wishes and capability.
- 2.1.4 Opioid treatment requires regular, documented assessment that addresses the "5As":
- analgesia
 - activity
 - adverse effects
 - affect
 - aberrant behaviour
- 2.1.5 The criteria for "opioid-responsiveness" may include but are not limited to:
- a) increase in function, as determined by an agreed activity or set of activities, assisted by instruments such as BPI⁸ or PEG⁹
 - b) absence of limiting side-effects, especially those that might interfere with sleep, learning and active self-management
 - c) reduction in pain, quantified by instruments such as BPI, PEG, VAS¹⁰, NRS¹¹
 - d) sustained response over time, not requiring dose escalation
- 2.1.6 If goals are met during a trial, then it is important to determine the lowest dose of opioid that is associated with sustained benefit. This dose may not be zero.
- 2.1.7 If the opioid trial goals are not met, then a process of weaning should be commenced. Specific weaning strategies in the context of transition to self-management include:
- 2.1.7.1 In situations where opioid therapy has been maintained for a long time without meaningful improvement in function, the desired outcome is weaning to cessation if possible. One practical strategy is to reduce the daily opioid dose each month by 10-25%.
- 2.1.7.2 If weaning is required after a shorter period of opioid therapy, such as after failure to achieve the goals of an opioid trial, or after a negotiated treatment phase for acute pain, then a faster rate of weaning is generally appropriate. One option is a step-wise reduction of the daily opioid dose each week by 10- 25%.
- 2.1.7.3 If weaning is required in response to significant adverse effects or opioid misuse, then daily step-wise reduction may be more appropriate. Alternatively, immediate opioid cessation and pharmacological treatment of withdrawal symptoms can be considered.
- 2.1.7.4 If an attempt at opioid weaning has proven unsuccessful, then the rate can be slowed. This can be achieved by reducing the size of the dose reduction and/or by increasing the time spent at each dose level (e.g. 2 or 3 months between reductions).

⁶ This could be incorporated into an "opioid contract".

⁷ The International Classification of Functioning Disability and Health model (ICF) describes body functions, activities and participation.

⁸ BPI: Brief Pain Inventory (Tai G, Jensen MP, Thornberg JI, Shouti BF. Validation of the Brief Pain Inventory for chronic non-malignant pain. J Pain 2004(2); 5:133-137.)

⁹ PEG Pain-Enjoyment-General Activity scale of pain intensity and interference (Krebs EE, Lorenz KA, Bair MJ, et al. Development and Initial Validation of the PEG, a Three-item scale Assessing Pain Intensity and Interference. J Gen Intern Med 2009; 24(6): 733- 738.)

¹⁰ VAS: visual analogue (pain) scale

¹¹ NRS: numerical rating (pain) scale

2.1.7.5 In cases where it becomes apparent during weaning that the primary problem is opioid dependence rather than pain, involvement of an Addiction Medicine service is recommended.

2.1.7.6 Use of complex pharmacological treatments to assist weaning should be undertaken only by practitioners accredited in such treatment modalities.

- 2.1.8 During the period of opioid weaning,
- ongoing attempts to develop pain self-management skills remain important
 - compliance with regulatory requirements remains essential
 - limited dispensing and urine drug screening may be considered.

2.2 Additional principles underpinning management of the patient already established on opioids (the “inherited” or “legacy” patient)

2.2.1 Reassessment of the social, psychological and biomedical contributors to the person’s presentation should be performed and repeated over time.

2.2.2 Consolidation of all opioid formulations to one opioid formulation should be undertaken, guided by contemporary equianalgesic tables.¹²

2.3 Additional principles underpinning initiating a trial in an opioid-naïve patient

2.3.1 A trial of opioid drug treatment may be considered after comprehensive assessment and trials of non-drug therapy and non-opioid drug treatment, as part of a multimodal plan facilitating self-management, according to principles 1.5 and 2.1.1 above.

2.3.2 Although short-acting opioids may be useful in determining initial opioid-responsiveness in CNCP, as in 2.1.5 above, they should not be prescribed over the longer term, out of consideration for the development of tolerance and the potential for positive reinforcement of drug-taking behaviour. A definitive trial should be determined using long-acting or modified-release opioid preparations.

2.3.3 Transdermal fentanyl should not be initiated in CNCP.

2.3.4 Ascertainment of opioid-responsiveness by titration of dose should be achievable within two months of initiation

2.3.5 Opioid-responsiveness should be evident at oral morphine equivalent oMEDD doses ≤ 60mg per day.^{13,14} If doses exceed this, specialist consultation should be sought.

2.4 Response to difficulty achieving or maintaining therapeutic goals in an opioid trial

2.4.1 Difficulty in establishing opioid-responsiveness in the context of the individually tailored goals of an opioid trial, as defined above, may be attributable to pharmacodynamic, pharmacokinetic or behavioural factors.

- Pharmacodynamic factors, such as non-responsiveness of distress or development of intolerable adverse effects, and pharmacokinetic factors, such as insufficient (or excessive) duration of effect, may respond to change in opioid preparation or change in dosing regimen.
- Behavioural factors, such as poor activity pacing, may respond reinforcement of pain self-management skills.

¹²As per FPM Opioid Calculator app v 2.7.1 and document [www.fpm.anzca.edu.au/documents/opioid-dose-equivalence.pdf]

¹³ NSW Therapeutic Advisory Group Inc., Preventing and managing problems with opioid prescribing for chronic non-cancer pain. NSW TAG: Sydney, 2015

¹⁴ https://aci.health.nsw.gov.au/chronic-pain/health-professionals/quick_steps_through_opioid_management

2.4.2 Variations in stability of dose and responsiveness over time, including apparent increase in dose requirements may reflect change in the underlying biomedical contribution, development of tolerance, changes in mood, social circumstances or other stressors, or development of aberrant drug-taking behaviour. Such situations require comprehensive reassessment.

2.4.3 Actions arising out of such reassessment may include:

- recalibration of goals of therapy
- reconsideration of other modes of therapy
- consultation with colleague(s)
- opioid reduction to the minimum effective dose or cessation

SYNOPSIS OF CURRENT EVIDENCE (2020)

Complex phenotype of CNCP

The complexity of the phenotype of CNCP needs to be appreciated in understanding what is the role effectiveness of opioid therapy. A recent Australian population study¹⁵ found, in a cohort of patients with CNCP who were taking long term opioid therapy, that two-thirds were unemployed or in receipt of a government benefit and almost half had low income. Furthermore, 80% of the cohort reported multiple pain conditions, 50% significant depression, 50% suicidal ideation, and more than 50% had a history of childhood abuse or neglect and over 30% had a lifetime alcohol use disorder. This is reflected in population studies that show that people maintained on long term opioid therapy for CNCP describe more troublesome pain and greater functional interference than people not on opioids. Such associations underline the need for comprehensive multidisciplinary assessment of people with CNCP.

Efficacy of opioids in CNCP

The efficacy of opioid therapy is supported by strong evidence from randomised controlled trials in acute pain and from systematic reviews in cancer pain, palliative care and opioid dependency/addiction. By contrast, recent systematic reviews in CNCP have concluded that, despite modest analgesic benefit in the short term, there is insufficient evidence to determine the effectiveness of long-term opioid therapy in terms of improving pain and function. The duration of the RCTs reviewed was less than four months, which is insufficient to adequately inform the long-term role of opioid treatment in CNCP.

Adverse effects of opioids in CNCP

Tolerance and other adverse effects are potential limiting factors with long term opioid use. There is also a dose-dependent risk of serious harms, especially when opioids are combined with other psycho-active agents including alcohol. Falls, cognitive impairment and gastrointestinal problems are well recognised clinically but have not been well studied over the long term. Better documented risks include opioid misuse and addiction, overdose and death, sleep apnoea, sexual and other endocrine dysfunction, driving impairment and opioid prescription to manage psychological distress (the “chemical coper”). An additional concern is that many patients on long term opioid therapy are co-prescribed benzodiazepines and the combination of these, potentially with other sedatives and alcohol, is associated with further increased risk of apnoea and death.

Responsible prescription of opioids in CNCP

Clinical experience and multiple studies have indicated that the use of high pain severity ratings is a poor basis for selection of patients for opioid prescription. Pain ratings are well-known to be influenced by multiple psychological and contextual factors. Patients with mental health and substance abuse problems are more likely to be prescribed chronic opioid therapy (See ‘Complex phenotype of CNCP’ above) and at higher doses than people without those risk factors. Once established, dependence on opioids makes it hard to wean and cease them despite lack of analgesic benefit.

Prescribing Opioids Safely

The oMEDD dose at which THN should be recommended remains a matter of conjecture and is more nuanced and complex than a simple number. The literature suggests that there is no safe dose of opioid and that THN should be considered with all/every opioid prescription based on a risk assessment. The 2022 study in South East Queensland reported by Salom et al. showed

¹⁵ (Campbell et al, 2015)

that widely available THN and brief education about recognising and overdose and how to use THN, such as the Monash Naloxone Patient Leaflet, saved an estimated 3 lives per day from inadvertent over doses²³⁴. Risk factors such as frailty, age <18 or >65 years, weight <50kg, comorbid medical conditions (respiratory conditions, liver or kidney disease, hypothyroid, body mass), concomitant medications, palliative care, disordered sleep, mental health disorder, and a child <18 in household, need to be considered in determining individual prescription and patient risk. Although an oMEDD >40mg and an >100mg are respectively associated with a four-fold and eleven-fold increased risk of a cardiorespiratory event⁵. The risk factors listed above and co-prescription of other sedatives, such as benzodiazepines, gabapentanoids and alcohol use elevates the risk and makes the risk assessment non-linear.

In Australia, 75 patients are hospitalised and 2-3 people die every day from prescribed opioids, with most being preventable by having naloxone at home. The Australian Government funds THN as part of the pharmaceutical Benefits Scheme (PBS), allowing people at risk of experiencing or likely to witness an opioid overdose, to access naloxone without a prescription, at no cost to themselves from pharmacies and other approved sites. THN is similarly available in a number of other countries around the world.

Screening for opioid risk

Screening for opioid risk has been recommended but at this point evidence of effectiveness is lacking. Screening for high-risk patients, treatment agreements and urine testing have not been shown to reduce overall rates of opioid prescribing, misuse, or overdose. Newer strategies aimed at reducing the risk of opioid misuse require evaluation. These include more selective prescription of opioids, avoidance of additional sedative hypnotics, prescription of lower doses, tamper resistant formulations and prescription monitoring programs.

Place of opioid use in CNCP

It is clear that opioid pharmacotherapy is not a core component of the management of patients with CNCP. Furthermore, issues of patient selection and duration of opioid therapy require further definition.

A focus on pain relief alone via the passive receipt of opioid therapy can distract both patient and prescriber from active self-management strategies. This raises the question of suitable therapeutic alternatives, an issue that remains only partially resolved given the modest gains reported from cognitive behavioural approaches. Clearly there are challenges in systematically reviewing studies with different treatment components and methodologies. Not all cognitive behavioural programs are the same. Hence the content and quality of multidisciplinary programs need further examination. Nevertheless, the benefits of the multidisciplinary approach are highlighted by studies showing improvement in pain and physical and emotional functioning after opioid cessation in a cognitive behavioural pain management. Strategies showing promise as components of the evolving multidisciplinary approach include neuroscience education, physical activity, nutrition, social engagement, mindfulness and other psychotherapies.

SELECTED BIBLIOGRAPHY

Phenotype

- Campbell G, Nielsen S, Bruno R, et al. The Pain and Opioids IN Treatment (POINT) study: characteristics of a cohort using opioids to manage chronic noncancer pain. *PAIN* 2015;156:231–242
- Edlund MJ, Fan MY, DeVries A, Braden JB, et al. Trends in use of opioids for chronic non-cancer pain among individuals with mental health and substance use disorders: the TROUP Study. *Clin J Pain* 2010;26:1-

² C. Salom, J. Maravilla, N. Thomas, J. Juckel, C. Daly and A. Peacock *et al.*, *Evaluation of the Pharmaceutical Benefits Scheme-subsidised Take Home Naloxone Pilot 2022*, University of Queensland, 2022, available at: <https://espace.library.uq.edu.au/view/UQ:7b4d303> [accessed 29 September 2025].

³ E. Behar, G.-M. Santos, E. Wheeler, C. Rowe and P. O. Coffin, 'Brief overdose education is sufficient for naloxone distribution to opioid users', *Drug and Alcohol Dependence*, 148 (2015), 209–12.

⁴ *Monash Naloxone Patient Leaflet 2020*, Monash University, available at: https://www.monash.edu/_data/assets/pdf_file/0008/2315159/June2020-Naloxone-Patient-Leaflet.pdf [accessed 6 March 2025].

⁵ G. M. Franklin, 'Opioids for chronic noncancer pain', *Neurology*, 83.14 (2014), 1277–84

- Blozik E, Laptinskaya D, Herrmann-Lingen C, Schaefer H, Kochen MM, Himmel W, Scherer M. Depression and anxiety as major determinants of neck pain: a cross sectional study in general practice. *BMC Musculoskelet Disord* 2009;10:13
- Eriksen J, Sjogren P, Bruera E, et al. Critical issues on opioids in chronic non-cancer pain. An epidemiological study. *Pain* 2006;125:172-179

Efficacy in acute and cancer pain and in ORT

- Schug SA, Palmer GM, Scott DA, Halliwell R, Trinca J (eds). *Acute Pain Management: Scientific Evidence*, 4E. Melbourne: Faculty of Pain Medicine and Australian and New Zealand College of Anaesthetists, 2015.
- Caraceni A, Hanks G, Kaasa S et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. *Lancet Oncol* 2012;13: e58-68
- NHS National Institute for Health and Clinical Excellence NICE guideline. Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults. May 2012
- Colson J, Koyyalagunta D, Falco FJE, Manchikanti L. A systematic review of observational studies on the effectiveness of opioid therapy for cancer pain. *Pain Physician* 2011;14:E85-102
- Amato L, Davoli M, Perucci C et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. *Journal of Substance Abuse Treatment* 2005;28(4):321-29

Efficacy in CNCP – reviews since 2015

- Petzke F, Klose P, Welsch P, Sommer C, Häuser W. Opioids for chronic low back pain: An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks of double-blind duration. *Eur J Pain*. 2020 Mar;24(3):497-517.
- Sommer C, Klose P, Welsch P, Petzke F, Häuser W. Opioids for chronic non-cancer neuropathic pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. *Eur J Pain*. 2020 Jan;24(1):3-18. doi: 10.1002/ejp.1494. Epub 2019 Nov 18.
- Welsch P, Petzke F, Klose P, Häuser W. Opioids for chronic osteoarthritis pain: An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks double-blind duration. *Eur J Pain*. 2019 Dec 26. doi: 10.1002/ejp.1522. [Epub ahead of print] duration. *Eur J Pain*. 2020 Jan;24(1):3-18.
- Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. *JAMA* 2018;319(9):872–82.
- McPherson S, Lederhos Smith C, Dobscha SK, et al. Changes in pain intensity after discontinuation of long-term opioid therapy for chronic noncancer pain. *Pain* 2018;159(10):2097–104.
- Busse JW., Wang L., Kamaleldin M., Craigie S et al. Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. *JAMA* 2018, 320(23), pp 2448-2460.
- Finnerup NB, Attal N, Harantoumi S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *The Lancet Neurology* 2015; 14:162-173
- Deyo RA, Von Korff M, Duhkoop D. Opioids for low back pain. *BMJ*. 2015 Jan 5;350
- Chou R, Turner JA, Devine EB, Hansen RN, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a National Institutes of Health pathways to prevention workshop. *Annals of Internal Medicine* 2015; doi:10.7326/M14-2559. Downloaded from: <http://annals.org/> on 01/14/2015

Efficacy in CNCP – reviews prior to 2015

- Manchikanti L, Ailinani H, Koyyalagunta D et al. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. *Pain Physician*. 2011;14(2):91-121
- Noble M, Treadwell JR, Tregear SJ et al. Long-term opioid management for chronic meta-analysis of effectiveness and side effects. *Canadian Medical Association Journal* 2006;174(11):1589–1594

Adverse effects

- Guilleminault C, Cao M, Yue HJ, Chawla P. Obstructive sleep apnoea and chronic opioid use. *Lung* 2010;188(6):459-468. doi:10.1007/s00408-010-9254-3
- Teichtahl H, Wang D. Sleep-disordered breathing with chronic opioid use. *Expert Opin Drug Saf*. 2007;6(6):641-649

- Webster LR, Choi Y, Desai H, Webster L, Grant BJ. Sleep-disordered breathing and chronic opioid therapy. *Pain Med*. 2008;9(4):425-32. doi: 10.1111/j.1526-4637.2007.00343
- Katz N, Mazer NA. The impact of opioids on the endocrine system. *Clin J Pain*. 2009;25(2):170-175
- Vuong C, Van Uum S, O'Dell L, Lutfy K, Friedman T. The effects of opioids and opioid analogues on animal and human endocrine systems. *Endocr Rev*. 2010;31(1):98-132
- Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. *Drug Saf*. 2011 Feb 1;34(2):125-156

Responsible prescription and risk assessment

- Hunter New England NSW Health. Reconsidering opioids. September 2020 [https://www.hnehealth.nsw.gov.au/data/assets/pdf_file/0020/420644/Reconsidering_opioids_September_2020.pdf]
- Gordon A, Cone EJ, DePriest AZ, Axford-Gatley RA, Passik SD. Prescribing opioids for chronic noncancer pain in primary care: risk assessment. *Postgrad Med*. 2014 Sep;126(5):159-166
- Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. *Pain Physician* 2012;15:ES67-92
- Cohen ML, Wodak AD. Opioid prescribing in general practice: a proposed approach. *Medicine Today* 13:24-32, 2012.
- Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic non-cancer pain: Prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline. *J Pain* 2009;10:131-146.
- Ballantyne JC, LaForge SL. Opioid dependence and addiction in opioid treated pain patients. *Pain* 2007;129:235-255
- Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. *Pain Med* 2005;6:107-112.
- Passik SD, Kirsch KL. The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. *Exp Clin Psychopharm* 2008; 16:400-404

Place of opioid use in multidisciplinary approach to CNCP

- Dowd H, Hogan MJ, McGuire BE, Davis M, et al. Comparison of an Online Mindfulness-based Cognitive Therapy Intervention with Online Pain Management Psychoeducation: A Randomized Controlled Study. *Clin J Pain*. 2015 Jan 6. [Epub ahead of print]
- Eccleston C, Palermo TM, de C Williams AC, Lewandowski HA, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. *Cochrane Database Syst Rev*. 2014;5:CD003968. doi: 10.1002/14651858. CD003968.pub4.
- Murphy JL, Clark ME, Banou E. Opioid cessation and multidimensional outcomes after interdisciplinary chronic pain treatment. *Clin J Pain*. 2013;29(2):109-117
- Sluka KA, O'Donnell JM, Danielson J, Rasmussen LA. Regular physical activity prevents development of chronic pain and activation of central neurons. *J Appl Physiol* 2013; 114:725-733
- Williams AC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database Syst Rev*. 2012;11:CD007407. doi: 10.1002/14651858. CD007407.pub3.
- Chiesa A, Serretti A. Mindfulness-based interventions for chronic pain: a systematic review of the evidence. *J Altern Complement Med*. 2011 Jan;17(1):83-93. doi: 10.1089/acm.2009.0546.
- Townsend CO, Kerkvliet JL, Bruce BK, Rome JD, et al. A longitudinal study of the efficacy of a comprehensive pain rehabilitation program with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission. *Pain* 2008;140(1):177-89

Maximizing Safe Use of Opioids and Take-Home Naloxone

- Salom C, Maravilla J, Thomas N, Juckel J, Daly C, Peacock A, et al. Evaluation of the Pharmaceutical Benefits Scheme-subsidised Take Home Naloxone Pilot 2022. <https://espace.library.uq.edu.au/view/UQ:7b4d303>
- Franklin GM. Opioids for chronic noncancer pain. *Neurology*. 2014;83(14):1277-84.
- Monash Naloxone Patient Leaflet 2020. https://www.monash.edu/_data/assets/pdf_file/0008/2315159/June2020-Naloxone-Patient-Leaflet.pdf Accessed 6/3/2025.
- Behar E, Santos G-M, Wheeler E, Rowe C, Coffin PO. Brief overdose education is sufficient for naloxone distribution to opioid users. *Drug and Alcohol Dependence*. 2015;148:209-12.

Faculty of Pain Medicine Professional Documents

POLICY – A document that formally states principle, plan and/or course of action that is prescriptive and mandatory.

STATEMENT – A document that describes where the college stands on a particular issue. This may include areas that lack clarity or where opinions vary. A statement is not prescriptive.

GUIDELINE – A document that offers advice on a particular subject, ideally based on best practice recommendations and information, available evidence and/or expert consensus. A guideline is not prescriptive.

This document has been prepared having regard to general circumstances, and it is the responsibility of the practitioner to have express regard to the particular circumstances of each case, and the application of this policy document in each case.

Professional documents are reviewed from time to time, and it is the responsibility of the practitioner to ensure that the practitioner has obtained the current version. Professional documents have been prepared having regard to the information available at the time of their preparation, and the practitioner should therefore have regard to any information, research or material which may have been published or become available subsequently.

Whilst the College and Faculty endeavours to ensure that documents are as current as possible at the time of their preparation, they take no responsibility for matters arising from changed circumstances or information or material which may have become available subsequently.

Promulgated: April 2020
Synopsis added: 2021
Date of current document: December 2021
Updated: October 2025

© Copyright 2025 – Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from ANZCA. Requests and inquiries concerning reproduction and rights should be addressed to the Chief Executive Officer, Australian and New Zealand College of Anaesthetists, 630 St Kilda Road, Melbourne, Victoria 3004, Australia. Email: ceoanzca@anzca.edu.au

Website: www.anzca.edu.au